stockrow
Friday 6 November 2026
Export RVTY’s income statement to Excel — free account
Revvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.
- Revenue
- +4.29%
- EPS
- +2.17%
- Free cash flow
- +27.0%
- Total debt
- −18.1%
Quarter to September 2026, against a year earlier
150.97
8.46
−5.31%
Follow RVTY
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 3.21% | 3.23% | 3.23% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
— | 6 | 6 | 6 | |
| 2.14% | 1.95% | 1.97% | 1.96% | ||
ROIC |
2.50% | 2.38% | 2.36% | 2.33% | |
Return on Tangible Assets |
15.72% | 16.08% | 17.68% | 17.38% | |
Average Days of Receivables |
85.28 | 88.90 | 86.95 | 95.17 | |
Free Cash Flow per Share |
0.00 | 5.11 | 4.49 | 4.37 | |
Free Cash Flow |
602.51 | 570.15 | 501.70 | 509.41 | |
Capital Expenditures |
(53.33) | (57.48) | (68.31) | (73.52) | |
| Other line items | |||||
Cash ROIC |
5.74% | 4.98% | 4.46% | 4.47% | |
Accounts Receivable Turnover |
4.30 | 4.25 | 4.44 | 4.15 | |
Accounts Payable Turnover |
7.65 | 7.62 | 7.63 | 7.32 | |
Inventory Turnover |
3.37 | 3.42 | 3.45 | 3.46 | |
Average Days of Payables |
45.95 | 46.14 | 46.71 | 52.41 | |
Days of Inventory on Hand |
109.43 | 105.38 | 106.67 | 107.24 | |
Tax Rate |
(0.11) | (0.09) | (0.10) | (0.11) | |
Research and Development Expense of Revenue |
7.25% | 7.41% | 7.58% | 7.56% | |
Selling, General and Administrative Expense of Revenue |
36.02% | 35.24% | 34.32% | 34.73% | |
Share Based Compensation of Revenue |
0.85% | 0.84% | 0.82% | 0.80% | |
Interest Coverage |
4.01 | 3.66 | 3.82 | 4.04 | |
Operating CF/Net income |
2.59 | 2.64 | 2.38 | 2.42 | |
Depreciation/Fixed assets |
0.93 | 0.91 | 0.90 | 0.86 | |
Capex/Depreciation |
(0.13) | (0.14) | (0.16) | (0.18) | |
Revenue per Share |
0.00 | 26.10 | 25.95 | 24.51 | |
Operating CF per Share |
0.00 | 5.62 | 5.10 | 5.00 | |
Capex per Share |
0.00 | (0.52) | (0.61) | (0.63) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.03 |
Columns are period end dates · fundamentals updated 5 Nov 2026